Join to access to all OVN content. Join for Free
FFPE: The Workhorse Behind NGS Testing
biomarker sequencing diagnostics translational research precision

FFPE: The Workhorse Behind NGS Testing


Share This Article



Summary

Exploring FFPE’s impact on precision oncology, NGS innovation, and the future of tissue stewardship in cancer care with leading Labcorp experts.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Kyle Strickland, Director of Medical Affairs and pathologist at Labcorp, and Dr. Erin Newburn, field application scientist and genomicist, for a deep dive into tissue stewardship and the pivotal role of FFPE specimens in precision oncology.

Together, the team demystifies how formalin-fixed paraffin-embedded (FFPE) samples have become the gold standard in both clinical and research settings for biomarker testing. They discuss the science behind tissue preservation, compare FFPE to fresh and frozen samples, and reveal the unique challenges these specimens present for next-generation sequencing. Explore the crucial pre-analytical factors influencing sample quality and how emerging innovations are pushing the boundaries of what’s possible in cancer diagnostics, clinical trials, and translational research.

Whether you’re a clinician seeking to optimize patient care, a researcher navigating limited samples, or simply curious about the future of precision medicine, this conversation provides practical insights and actionable tips directly from the experts transforming the field.

Tune in now to discover how the workhorse of pathology is powering a new era in oncology.

Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
AI-powered real-world evidence: Strategically enhancing value and access
Partner Avatar Envision Pharma Group

AI-powered real-world evidence: Strategically enhancing value and access

Article
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?
OVN Avatar Neil Carleton and Priscilla F. McAuliffe

Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?

Article
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
OVN Avatar Timothy Qi, Tyler Dunlap, Yanguang Cao1

Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Explore OVN